380 related articles for article (PubMed ID: 36855206)
21. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
[TBL] [Abstract][Full Text] [Related]
22. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Tadbiri S; Peyrin-Biroulet L; Serrero M; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Gilletta C; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Fumery M; Claudepierre P; Bouhnik Y; Amiot A;
Aliment Pharmacol Ther; 2018 Feb; 47(4):485-493. PubMed ID: 29250803
[TBL] [Abstract][Full Text] [Related]
23. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
24. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
[TBL] [Abstract][Full Text] [Related]
25. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW
Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease.
Núñez-Gómez L; Mesonero-Gismero F; Albillos-Martínez A; López-Sanromán A
Gastroenterol Hepatol; 2018 Nov; 41(9):576-582. PubMed ID: 30054143
[TBL] [Abstract][Full Text] [Related]
27. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
Hanauer SB; Stathopoulos G
Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
[TBL] [Abstract][Full Text] [Related]
28. Experience with the use of low-dose methotrexate for inflammatory bowel disease.
Soon SY; Ansari A; Yaneza M; Raoof S; Hirst J; Sanderson JD
Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):921-6. PubMed ID: 15316419
[TBL] [Abstract][Full Text] [Related]
29. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
[TBL] [Abstract][Full Text] [Related]
30. [Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease].
Gomollón F; Rubio S; Charro M; García-López S; Muñoz F; Gisbert JP; Domènech E;
Gastroenterol Hepatol; 2015 Jan; 38(1):24-30. PubMed ID: 25454602
[TBL] [Abstract][Full Text] [Related]
31. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
[TBL] [Abstract][Full Text] [Related]
32. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.
Kozarek RA; Patterson DJ; Gelfand MD; Botoman VA; Ball TJ; Wilske KR
Ann Intern Med; 1989 Mar; 110(5):353-6. PubMed ID: 2492786
[TBL] [Abstract][Full Text] [Related]
33. Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study.
Thomas PWA; den Broeder N; Derikx M; Kievit W; West RL; Russel MGVM; Jansen JM; Römkens TEH; Hoentjen F
Inflamm Bowel Dis; 2022 Dec; 28(12):1813-1820. PubMed ID: 35134917
[TBL] [Abstract][Full Text] [Related]
34. Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis.
Bjarnason I; Hayee B; Pavlidis P; Kvasnovsky C; Scalori A; Sisson G; Charlesworth A; Shaikh H; Bjornsson E; Heneghan MA
EBioMedicine; 2015 Oct; 2(10):1523-7. PubMed ID: 26629548
[TBL] [Abstract][Full Text] [Related]
35. Pancreatitis in inflammatory bowel diseases.
Pitchumoni CS; Rubin A; Das K
J Clin Gastroenterol; 2010 Apr; 44(4):246-53. PubMed ID: 20087199
[TBL] [Abstract][Full Text] [Related]
36. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
Teixeira FV; Damião AOMC; Kotze PG
Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
[TBL] [Abstract][Full Text] [Related]
37. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Vuitton L; Koch S; Peyrin-Biroulet L
Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
[TBL] [Abstract][Full Text] [Related]
38. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).
Ruther U; Nunnensiek C; Muller HA; Bader H; May U; Jipp P
Hepatogastroenterology; 1998; 45(21):691-9. PubMed ID: 9684118
[TBL] [Abstract][Full Text] [Related]
39. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
40. [Articular and extraarticular involvement in inflammatory bowel diseases].
Nitsche A; Tejeda A; Gallo JE; Chianello M
Acta Gastroenterol Latinoam; 1993; 23(3):151-8. PubMed ID: 8296515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
